Find Clinical Trials & Studies

Visit the Research & Education Institute

ZL-1310 vs Investigator s Choice Chemotherapy in Participants with Relapsed Small Cell Lung Cancer

I'm Interested!

Please call
1-866-373-1464

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Lung

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

Principal Investigator
Afshin Dowlati MD

Department/Division
Cancer (Thoracic)

UH IRB: 26-402
StudyID: ZLAB1525
ClinicalTrials.gov: NCT07218146

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464